Global /Israel /Healthcare /Medical Devices /XTLB

XTL Biopharmaceuticals Ltd.

XTLB

• TLV: XTLB • Delayed

3ILA 44%

0.0088 USD

As of 13 June 2026, XTL Biopharmaceuticals Ltd. has a market cap of $5.75M USD, ranking #43888 globally and #579 in Israel. It ranks #3892 in the Healthcare sector, and #824 in the Medical Devices industry.

Global Rank

43888

Country Rank

579

Sector Rank

3892

Industry Rank

824

Key Stats

Market Cap

$5.75MUSD

17.03M ILS

Enterprise Value

$5.58MUSD

16.45M ILS

Revenue (TTM)

$1.1MUSD

3.26M ILS

Net Income (TTM)

-$7.17MUSD

-21.25M ILS

PS Ratio

5.2

PB Ratio

-107.6

Company Profile

Country (HQ)

Israel

Sector

Healthcare

Industry

Medical Devices

CEO

Noam Band open_in_new

Employees

Founded

1993

Website

xtlbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
44%	30%	24%	-3.7%	-38%	8.3%	-47%	-40%	-79%

News

Markets

Exchange	Ticker	Price	Quotes
Tel Aviv Stock Exchange (TLV) MIC: XTAE PRIMARY	XTLB אקס טי אל ביופרמסוטיקלס בעמ ISIN: IL0010854979 Shares Out.: Shares Outstanding: 946.243M¹ Shares Float: 596.747M² TV: TradingView: TASE: XTLB SA: Stock Analysis: TLV: XTLB YF: Yahoo Finance: XTLB.TA GF: Google Finance: TLV: XTLB BA: Barron's: XTLB MS: Morningstar: XTAE: XTLB	3 ILA	TV: TradingView: TASE: XTLB SA: Stock Analysis: TLV: XTLB YF: Yahoo Finance: XTLB.TA GF: Google Finance: TLV: XTLB BA: Barron's: XTLB MS: Morningstar: XTAE: XTLB
NASDAQ MIC: XNAS	XTLB ISIN: US98386D4060 Shares Out.: Shares Outstanding: 2.366M¹ Shares Float: 2.307M² TV: TradingView: NASDAQ: XTLB SA: Stock Analysis: NASDAQ: XTLB YF: Yahoo Finance: XTLB GF: Google Finance: NASDAQ: XTLB NQ: NASDAQ: XTLB BA: Barron's: XTLB MS: Morningstar: XNAS: XTLB	3.56 USD	TV: TradingView: NASDAQ: XTLB SA: Stock Analysis: NASDAQ: XTLB YF: Yahoo Finance: XTLB GF: Google Finance: NASDAQ: XTLB NQ: NASDAQ: XTLB BA: Barron's: XTLB MS: Morningstar: XNAS: XTLB

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Similar Companies

Industry: Medical Devices (Israel)

Name	Market Cap (USD) diff.	PE	Country
InMode Ltd. NASDAQ: INMD	$884.49M 15K%	9.8	Israel
BrainsWay Ltd. TLV: BWAY	$651.25M 1.93B ILS 11K%	83.0	Israel
Alpha Tau Medical Ltd. NASDAQ: DRTS	$648.63M 11K%	-	Israel
SofWave Medical Ltd. TLV: SOFW	$527.8M 1.56B ILS 9K%	97.0	Israel
Sisram Medical Ltd. SHEK: 1696	$174.5M 1.37B HKD 3K%	9.2	Israel
Bonus BioGroup Ltd. TLV: BONS	$167.52M 496.46M ILS 3K%	-	Israel

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 3M%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 3M%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 3M%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 2M%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 2M%	38.3	United States
Medtronic plc NYSE: MDT	$101.9B 2M%	22.2	Ireland

chevron_leftBack